i3 Funding
Discover what the i3 Family of Funds offers to Mount Sinai innovators.
About i3
Launched by MSIP, the i3 Family of Funds offers a variety of technology commercialization funding for Mount Sinai innovators. “i3” stands for innovation, inflection, and impact, the three ingredients necessary to expediate commercializing relevant inventions and transforming a research idea into a mature, commercial-ready technology. There are three different opportunities that make up the Family, with different criteria in an effort to enable a wide range of inventors from Mount Sinai’s research and clinical communities. Learn more about each opportunity below.
Types of Funding
Get to know the three opportunities that make up the i3 Family of Funds: i3 Prism, i3 Genesis, and i3 Accelerator.
i3 Prism
i3 Prism is an early-stage technology commercialization fund focused on women and Black, Indigenous and People of Color (BIPOC) healthcare innovators at Mount Sinai who aim to bring new healthcare solutions to patients and society, and advance technologies to the next level from a commercial perspective. Selected applicants will receive up to $33K in funding, which will be distributed based on the achievement of milestones.
Application Period: February 5 to March 5, 2024.
Types of Eligible Technologies: Technologies from all healthcare fields are acceptable, including, but not limited to: therapeutics, diagnostics, medical devices, and digital health.
Application Process: Innovators who meet the eligibility criteria can submit a proposal during the time period above. Submitted proposals will be distributed for review among Mount Sinai experts to be scored based on project feasibility and market risks against the budget and milestones provided.
i3 Genesis
i3 Genesis is the inaugural funding program for early-stage healthcare technologies at Mount Sinai with clear potential for commercialization. This program aims to support and translate innovations by providing funding to achieve value inflection points.
Types of Eligible Technologies: Technologies from all healthcare fields are acceptable, including, but not limited to: therapeutics, diagnostics, medical devices, and digital health.
Application Process: Innovators must meet the eligibility criteria.
i3 Accelerator
i3 Accelerator advances the development of discoveries from Mount Sinai into groundbreaking technologies that aim to help the patient population. The goal is to increase the pace of commercialization for a promising technology by applying a strategic and milestone-driven investment. Researchers collaborate with MSIP to execute a project strategy to advance technologies beyond the lab bench.
Types of Eligible Technologies: Technologies from all healthcare fields are acceptable, including, but not limited to: therapeutics, diagnostics, medical devices, and digital health.
Application Process: i3 Accelerator projects must be nominated by MSIP’s Business Development (BD) representatives. Innovators must meet the eligibility criteria.
Frequently Asked Questions
- i3 Accelerator (launched in 2018): milestone-based funding for more established healthcare technologies with potential for commercial translation after the completion of milestones.
- i3 Genesis (launched in January 2022): funding for early-stage healthcare discoveries with the potential to become commercialized, with an objective to generate proof-of-concept data.
- i3 Prism (launching March 2022): funding for technology commercialization efforts by female and/or minority innovators to advance early-stage technologies.
i3 Prism, i3 Genesis, and i3 Accelerator can include multiple PIs, as long as they are part of Mount Sinai (e.g. faculty, staff, postdoc, etc.). Please visit the respective program pages to learn more.
For inquiries about i3 Genesis and i3 Accelerator, please reach out to Louise Lammers, PhD, Director, Business Development, Emerging Assets at louise.lammers@mssm.edu and William Chiang, PhD, Business Development Consultant, at william.chiang@mssm.edu. For inquiries about i3 Prism, please reach out to Cynthia Cleto, MS, Senior Director of Outreach, Entrepreneurship and Special Programs at cynthia.cleto@mssm.edu and Steffanie Haripersaud, MHA, Program Manager, at steffanie.haripersaud@mssm.edu.
At this time, i3 Genesis funding is not available. Typically, applicants can submit the same project as long as the development plans fit the criteria for the funds and the applicant meets the eligibility requirements. Please keep in mind that if you get awarded i3 Genesis funding, you are no longer eligible for i3 Prism funding.